METHODS:
l This comparative analysis includes all pharmaceuticals with an marketing authorization which either applied for initial admission to reimbursement (France), first launched (Germany) or assessed for recommendation (UK). The cutting date has been fixed at December 2015 in order to have full year timeframes. The analysis therfore will be updated early 2017 with data up to end 2016. The PRISMACCESS databases was searched systematically to identify approved oncology therapies and collect the specific data (criteria see Outcome metrics in all three countries are different. In order to use a comparable decision measure in the three countries of interest a matrix for common outcome terminology was developed (see table 2). 
RESULTS:
l Since 2011, EMA issued positive opinions for 48 New Medical Entities (NMEs); further 6 submission procedures ended with negative outcomes (i.e. 2 manufacturers have withdrawn prior to the CHMP opinion and 4 products receive negative CHMP opinions and a negative EU commission decision.) l An marketing authorization from the EU commission was granted to 47 applicants; one applicant withdrew its application after the CHMP had issued a conditional marketing authorization (i.e. after a decision based on phase II trial results: the confirmative phase III trial -results were available just after CHMP's opinion -did not cross the statistical significance threshold). In Germany 32 decisions of the 44 HTA submissions commenced; 26 were positive in Germany ('major' or 'considerable'; 'minor'); 6 were negative -'no' added benefit. For 10 submissions, German G-BA claimed not yet be able to take a decision (i.e. 'added benefit not quantifiable') l In the United Kingdom, the degree recommendations accounted for as positive decisions was generally lower with NICE, 19 (68%) and SMC, 14 (45%) positive outcomes only; in Scotland, 17 new medicines were initially not recommended for use in the National Health Service (NHS). l HTA outcomes were similar (magnitude) or identical in 8 cases totally only; in 4 cases outcomes were positive across all four evaluating boards, in 4 cases consistently negative. l HTA decision patterns differed according to different primary endpoints of the pivotal trial:
OVERALL SURVIVAL:
If progression free survival is taken as the criteria to review the decision results: o G-BA assigned 9 drugs a considerable added benefit; 6 drugs a minor added benefit and for 1 drug no added benefit was proven. o French HAS decided for significant SMR for 6 drugs; minor for another 6 drugs, no actual benefit for 3 drugs and for one it was insufficient. o NICE recommended 8 drugs; further 6 drugs, demonstrating a modest but statistically significant overall survival gain, were not recommended. o SMC recommended 5 drugs, but 9 drugs showing a reduction of the mortality rate were not recommended.
PROGRESSION FREE SURVIVAL (PFS)
If progression free survival is taken as the criteria to review the decision results: o G-BA assigned a considerable added benefit for 5 drugs; a minor for 3 drugs and no added benefit was proven for 3 drugs in relation to PFS. o HAS approved 7 drugs a considerable SMR; a minor for further 7 drugs and no actual benefit for 3 drugs. o NICE recommended all 9 drugs with PFS as primary endpoint in the pivotal trial. o SMC recommended just half of the drugs (6 out of 12) showing a PFS prolongation.
l No major differences in the HTA decision timing patterns -that depend on the companies' dossier submission strategies and depend partly on differing judicial timelines for HTA dossier submission -could be ascertained (see table 3 ). In median, the first HTA decision was issued 5.1 months after approval (range 2.4-18.6 months); an additional time span of 7.3 months (median) was required to get a decision by all four appraisal bodies (n=24).
l For Teysuno, Pixuvri and Provenge -the marketing authorization holders of these 3 drugs met the EMA definition of 'small and medium sized companies' -the issuing of the first HTA decision took at least 12 months (see table 3) after approval was granted. In terms of the procedural times, drug approval by EMA required in median 13.8 months (95% CI for the median: 12.7-14.6).
l HTA issuing in France were very rapidly issued (additional 1.6 months in median, 95% CI 0.7-3.4).
l
In Germany, decisions took longer, but the predictability of the decision time point was very high (median 5.6 months, 95% CI 5.5-5.7).
l Although decisions in Scotland were taken as rapidly as France, their timing until issuing was more variable (median 5.4 months, 95% CI 4.7-8.4). In contrast, NICE decisions required more than 1 year with a high variability in the timing patterns (Median 12.1 months, 95% CI 8.4-14.1). For NICE the timing in anyway is more difficult to ascertain as submissions for HTA appraisal is already possible prior to marketing authorization. 
